Batoclimab is a monoclonal antibody commercialized by Immunovant, with a leading Phase III program in Myasthenia Gravis. According to Globaldata, it is involved in 23 clinical trials, of which 7 were completed, 10 are ongoing, 4 are planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Batoclimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Batoclimab is expected to reach an annual total of $702 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Batoclimab is under development for the treatment of idiopathic thrombocytopenic purpura (ITP), membranous nephropathy, pemphigus vulgaris, lupus nephritis (LN), myasthenia gravis (MG), Graves' ophthalmopathy, chronic inflammatory demyelinating polyneuropathy (CIDP), Graves disease (GD) and neuromyelitis optica (NMO). It is a fully human monoclonal antibody IgG1 targeting the Fc neonatal receptor (FcRn). It is administered subcutaneously and developed based on OmniAb technology.
It was under development for warm autoimmune hemolytic anemia.
Immunovant, a subsidiary of Roivant Sciences Ltd, is a biopharmaceutical company that develops antibodies for the treatment of autoimmune diseases. The company’s pipeline products include batoclimab and MVT-1402. Its batoclimab treats myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy and graves disease. It is also evaluating its IMVT-1402, for the treatment of autoimmune disease. The company seeks to collaborate with HanAll Biopharma Co Ltd for the research and development of next-generation FcRn inhibitors. The company operates in Switzerland, Bermuda and the US. Immunovant is headquartered in New York, the US.
The operating loss of the company was US$218.3 million in FY2023, compared to an operating loss of US$156 million in FY2022. The net loss of the company was US$211 million in FY2023, compared to a net loss of US$156.7 million in FY2022.
For a complete picture of Batoclimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.